Public dataset
Recorded enzyme and transporter findings by polarity
Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.
What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
- Public rows
- 8,404
- Generated
- Schema version
- 1.3.0
Coverage
What this run contains
- Medicine–counterparty–role groups
- 8,404
- Source sentence records
- 20,358
- Asserted sentences
- 4,700
- Denied sentences
- 7,494
- Polarity not recorded
- 8,164
- Medicines represented
- 755
- Counterparties represented
- 36
- Corpus records considered
- 9,855
- All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
- inducer groups
- 617
- inhibitor groups
- 3,131
- not_recorded groups
- 3,074
- substrate groups
- 1,582
Method
How the rows were made
- A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
- A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
- Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
- Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
- The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.
Limits
Read these before using a row
- A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
- This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
- ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
- A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
- 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
- Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
- 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
- 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
- The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
- The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
- A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
- Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.
Provenance
Source examples
Abacavir · CYP3A4 inhibitor
2 asserted · 2 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.
Abacavir · BCRP substrate
0 asserted · 4 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.
Abacavir · CYP2C9 not_recorded
0 asserted · 0 denied · 2 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).
Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| medicineName | string | Recorded medicine name; not normalized for display style. |
| counterparty | string | The exact recorded counterparty spelling. |
| role | string | SUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role. |
| assertedCount | number | Sentence records whose polarity is ASSERTED. |
| deniedCount | number | Sentence records whose polarity is NEGATED. |
| polarityNotRecordedCount | number | Sentence records for which the parser did not settle assertion or denial. |
| sentences | sentence[] | Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated. |
Reader
Search and filter the rows
Showing 2,261–2,270 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 2261
- Medicine slug
- dutasteride
- Medicine name
- Dutasteride
- Enzyme or transporter
- CYP2D6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than steady-state serum concentrations in humans.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than steady-state serum concentrations in humans.
Projected row 2262
- Medicine slug
- dutasteride
- Medicine name
- Dutasteride
- Enzyme or transporter
- CYP2E1
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.
Projected row 2263
- Medicine slug
- dutasteride
- Medicine name
- Dutasteride
- Enzyme or transporter
- CYP3A4
- Role
- INHIBITOR
- Asserted sentences
- 4
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
However, based on in vitro data, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, and ciprofloxacin.
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Calcium Channel Antagonists: In a population pharmacokinetics analysis, a decrease in clearance of dutasteride was noted when coadministered with the CYP3A4 inhibitors verapamil (-37%, n = 6) and diltiazem (-44%, n = 5).
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
However, based on in vitro data, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, and ciprofloxacin.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Calcium Channel Antagonists: In a population pharmacokinetics analysis, a decrease in clearance of dutasteride was noted when coadministered with the CYP3A4 inhibitors verapamil (-37%, n = 6) and diltiazem (-44%, n = 5).
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist that is not a CYP3A4 inhibitor, was coadministered with dutasteride (+7%, n = 4).
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist that is not a CYP3A4 inhibitor, was coadministered with dutasteride (+7%, n = 4).
Projected row 2264
- Medicine slug
- dutasteride
- Medicine name
- Dutasteride
- Enzyme or transporter
- CYP3A4
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 6
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In addition, the 15-hydroxydutasteride metabolite was formed by CYP3A4.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than steady-state serum concentrations in humans.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In addition, the 15-hydroxydutasteride metabolite was formed by CYP3A4.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than steady-state serum concentrations in humans.
Projected row 2265
- Medicine slug
- dutasteride
- Medicine name
- Dutasteride
- Enzyme or transporter
- CYP3A5
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:2ee1eef5-8ec7-46c1-b4fa-13184915448f (opens source in a new tab)
Dutasteride label
Version not recorded · Effective date not recorded
In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes.
Projected row 2266
- Medicine slug
- duvelisib
- Medicine name
- Duvelisib
- Enzyme or transporter
- BCRP
- Role
- INHIBITOR
- Asserted sentences
- 0
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Duvelisib does not inhibit OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, BCRP, or P-gp.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Duvelisib does not inhibit OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, BCRP, or P-gp.
Projected row 2267
- Medicine slug
- duvelisib
- Medicine name
- Duvelisib
- Enzyme or transporter
- BCRP
- Role
- SUBSTRATE
- Asserted sentences
- 4
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Duvelisib is a substrate of P-glycoprotein (P-gp) and BCRP in vitro.
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
In Vitro Studies Duvelisib is a substrate of P-glycoprotein (P-gp) and breast cancer-resistant protein (BCRP).
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Duvelisib is a substrate of P-glycoprotein (P-gp) and BCRP in vitro.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
In Vitro Studies Duvelisib is a substrate of P-glycoprotein (P-gp) and breast cancer-resistant protein (BCRP).
Projected row 2268
- Medicine slug
- duvelisib
- Medicine name
- Duvelisib
- Enzyme or transporter
- CYP3A4
- Role
- INDUCER
- Asserted sentences
- 4
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Strong and Moderate CYP3A4 Inducers Coadministration of a single COPIKTRA 25 mg dose with rifampin (strong CYP3A4 inducer) 600 mg once daily for 7 days in healthy adults decreased duvelisib C max by 66% and AUC by 82% [see Dosage and Administration ( 2.5 ) and Drug Interactions ( 7.1 )] .
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Co-administration of etravirine (moderate CYP3A4 inducer) 200 mg twice daily of etravirine for 12 days with a single COPIKTRA 25 mg dose in healthy adults decreased duvelisib C max by 16% and AUC by 35%. [see Dosage and Administration ( 2.5 ) and Drug Interactions ( 7.1 )] .
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Strong and Moderate CYP3A4 Inducers Coadministration of a single COPIKTRA 25 mg dose with rifampin (strong CYP3A4 inducer) 600 mg once daily for 7 days in healthy adults decreased duvelisib C max by 66% and AUC by 82% [see Dosage and Administration ( 2.5 ) and Drug Interactions ( 7.1 )] .
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Co-administration of etravirine (moderate CYP3A4 inducer) 200 mg twice daily of etravirine for 12 days with a single COPIKTRA 25 mg dose in healthy adults decreased duvelisib C max by 16% and AUC by 35%. [see Dosage and Administration ( 2.5 ) and Drug Interactions ( 7.1 )] .
Projected row 2269
- Medicine slug
- duvelisib
- Medicine name
- Duvelisib
- Enzyme or transporter
- CYP3A4
- Role
- INHIBITOR
- Asserted sentences
- 4
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Drug Interaction Studies CYP3A4 Inhibitors Coadministration of a single COPIKTRA 10 mg dose with ketoconazole (strong CYP3A4 inhibitor) at 200 mg BID for 5 days in healthy adults increased duvelisib C max by 1.7-fold and AUC by 4-fold.
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Based on physiologically-based pharmacokinetic (PBPK) modeling and simulation, the increase in duvelisib exposure at steady state is estimated to be ~2-fold when coadministered with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 ) and Drug Interactions ( 7.1 )] .
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Drug Interaction Studies CYP3A4 Inhibitors Coadministration of a single COPIKTRA 10 mg dose with ketoconazole (strong CYP3A4 inhibitor) at 200 mg BID for 5 days in healthy adults increased duvelisib C max by 1.7-fold and AUC by 4-fold.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Based on physiologically-based pharmacokinetic (PBPK) modeling and simulation, the increase in duvelisib exposure at steady state is estimated to be ~2-fold when coadministered with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 ) and Drug Interactions ( 7.1 )] .
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
PBPK modeling and simulation estimated no effect on duvelisib exposures from concomitantly used mild or moderate CYP3A4 inhibitors.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
PBPK modeling and simulation estimated no effect on duvelisib exposures from concomitantly used mild or moderate CYP3A4 inhibitors.
Projected row 2270
- Medicine slug
- duvelisib
- Medicine name
- Duvelisib
- Enzyme or transporter
- CYP3A4
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Metabolism Duvelisib is primarily metabolized by cytochrome P450 CYP3A4.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:e3c5ac56-e1f6-473a-bc73-687836534780 (opens source in a new tab)
Duvelisib label
Version not recorded · Effective date not recorded
Metabolism Duvelisib is primarily metabolized by cytochrome P450 CYP3A4.
Access
Query or download the projection
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=2260Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- role
- Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
- counterparty
- Exact recorded counterparty spelling.
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.